Keiretsu Capital — 2015 Investments
2 investments dated 2015 · listed companies and verified rows first · show all
Clinical-stage specialty pharma developing a combination drug to treat a range of addictions, licensed from LSU Health Sciences Center.
BiotechSudbury, US
Robert B. Linke(Executive Officer, Director)
BoardRoss Barrett(Director)Franz Hefti(Director)John Beaird(Director)Joseph Lovett(Director)
Co-investorsInnovation CatalystKeiretsu ForumLouisiana Funds
LumiThera develops the Valeda Light Delivery System, an FDA-authorized photobiomodulation (PBM) device that applies multiple light wavelengths to treat early and intermediate dry age-related macular degeneration (AMD).
BiotechHealthtechMedical DevicesPoulsbo, US
Tracy Puckett(Executive Officer)Clark Tedford(Executive Officer, Director)inScott Bradley(Executive Officer)inDuane Morrison(Executive Officer)inCindy Croissant(Executive Officer)Ryan Montecucco(Executive Officer)
Co-investors3E Bioventures CapitalEFung CapitalKeiretsu ForumLife Sciences Greenhouse InvestmentsImagine Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.




